MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$730,571
Net Income
-$2,752,681
Net Profit Margin
-376.78%
EPS
-$0.26
Unit: Dollar

Income Statement
2026-06-30
2026-03-31
2025-12-31
Revenues
730,571 353,375 511,283.25*
Cost of revenues
425,844 290,491 360,148*
Gross profit
304,727 62,884 151,135.25*
Sales, general and administrative
1,291,318 1,352,758 835,710.75*
Research and development
257,632 153,482 148,142.25*
Total operating expenses
1,548,950 1,506,240 983,853*
Operating loss
-1,244,223 -1,443,356 -832,717.75*
Interest expense
272,245 267,008 39,051.75*
Interest income
14,476 6,653 5,349.75*
Loss on change in fair value of warrant liability
--148,766 1,934.25*
Loss on issuance of convertible note
-4,236 -322,359 -70,191*
Other expense, net
-115 --28.75*
Total other (expense) income
-262,120 -731,480 -101,987.5*
Net loss
-1,506,343 -2,174,836 -934,705.25
Deemed dividend on warrant modifications
1,124,676 --
Preferred stock dividends
121,662 -54,192 -
Net loss attributable to common stockholders
-2,752,681 -2,120,644 -
Basic EPS
-0.26 -0.28 -0.19
Diluted EPS
-0.26 -0.28 -0.19
Basic Average Shares
10,790,722 7,657,229 4,930,287
Diluted Average Shares
10,790,722 7,657,229 4,930,287
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net lossattributable to common...-$2,752,681 Net loss-$1,506,343 Deemed dividend onwarrant modifications$1,124,676 Preferred stock dividends$121,662 Revenues$730,571 Operating loss-$1,244,223 Total other (expense)income-$262,120 Gross profit$304,727 Interest income$14,476 Cost of revenues$425,844 Total operatingexpenses$1,548,950 Interest expense$272,245 Loss on issuance ofconvertible note-$4,236 Other expense, net-$115 Sales, general andadministrative$1,291,318 Research and development$257,632

20 20 Biolabs, Inc. (AIDX)

20 20 Biolabs, Inc. (AIDX)